方美娟博士，副教授
个人简历
方美娟博士，厦门大学药学院副教授、福建省高层次人才。主要研究方向是发现人类疾病关键靶标（例如核受体，蛋白激酶和表观遗传酶）的选择性小分子调控剂，探索这些功能小分子调控靶标干预疾病的作用机制，并对功能小分子进行药学研究（构效关系、药代动力学和毒理学研究），以期发展针对癌症及其他炎症性疾病的“靶向治疗”药物。现已发现肿瘤、急性肺损伤等炎症相关疾病的多个靶向治疗创新小分子候选药物，包括RXRa小分子配体BPA-B9，CDK9小分子抑制剂XPW1、XM-A32、XM-B19等， Nur77小分子调控剂（XN-NB1、XN-8b、ja、XN-lq53、DHA-EA等。主持1项国家自然科学基金青年项目（完成）、2项福建省自然科学基金（1项在研）、1项厦门市自然科学基金项目（在研）；主持多项横向项目；作为主要研究者参与863子课题、十一五重大新药创制专项等研究项目。至2025年2月，方美娟博士作为第一通讯或共同通讯，在本专业领域重要刊物上发表SCI论文约65篇；同时作为主要发明人获授权中国专利十六个。
工作经历
2011起，厦门大学药学院，副教授，硕导。
2014.06-2015.06， 美国加州大学旧金山分校， Research Associate。
2006-2011起，厦门大学药学院，药学系，讲师，硕导。
教育背景
2001.9—2006.7 厦门大学化学化工学院，有机化学专业，理学博士
1997.9—2001.7 厦门大学化学化工学院化学系，理学学士
近五年发表的论文
[1] Yin Cao(#), Sen Huang(#), Yaohui He, Yuxiang Zhang, Simian Chen, Mengxian Huang, Fengming He, Shutong Chen, Di Wang, Ziying Yang, Xinwei Zhao, Xiumin Wang, Zhen Wu, Mingtao Ao(*), Yingkun Qiu(*), Meijuan Fang(*). Discovery of 4-(2-(methylamino)thiazol-5-yl)pyrimidin-2-amine derivatives as novel cyclin-dependent kinase 12 (CDK12) inhibitors for the treatment of esophageal squamous cell carcinoma. Bioorg Chem, 2025 FEB; 155: 108113. (JCR一区)
[2] Jun Chen(#), Taige Zhao(#), Wenbin Hong(#), Hongsheng Li, Mingtao Ao, Yijing Zhong, Xiaoya Chen, Yingkun Qiu, Xiumin Wang, Zhen Wu, Tianwei Lin, Baicun Li(*), Xueqin Chen(*), Meijuan Fang(*). Discovery of a novel exceptionally potent and orally active Nur77 ligand NB1 with a distinct binding mode for cancer therapy. Acta Pharm. Sinica B, 2024 DEC; 14(12): 5493-5504. (JCR一区，药学TOP期刊)
[3] Hongyu Hu(#), Fangfang Wen(#), Tidong Zhen(#), Minda Zhang, Jingbo Qin, Jiangang Huang, Zhirong Chen, Mingyue Yu, Shengwei Hu, Meijuan Fang(*), Jin-Zhang Zeng(*). Design, synthesis, and biological evaluation of N1-(2-(adamantan-1-yl)-1H-indol-5-yl)-N2-(substituent)-1,2-dicarboxamides as anticancer agents targeting Nur77-mediated endoplasmic reticulum stress. Bioorg Chem, 2025 FEB 12; 155: 108113. (JCR一区)
[4] Zhe-Wei Yu(#), Jing Wang(#), Fan-Hong Lin(#), Feng-Ming He, Hong-Sheng Li, Su-Su Wang, Mei-Juan Fang(*), Bai-Cun Li(*), Ying-Kun Qiu(*), A comprehensive study on solvent effect and establishment of n-hexane solvent system based normal-phase liquid chromatography × reversed-phase liquid chromatography for isolation of natural products. J Chromatogr A, 2024 SEP 27; 1733: 465278. (JCR一区)
[5] Hua Fang(#), Xiumei Wang, Mengyu Li, Mengxian Huang, Yiping Zhang, Taige Zhao, Cuiling Sun, Min Xu, Wenhui Jin, Weizhu Chen, Meijuan Fang(*). Synthesis and biological evaluation of novel carboxylic acid DHA-alkanolamine derivatives as anti-inflammatory agents by targeting Nur77. J Mol Struct, 2025 FEB 5; 1321: 139738. (JCR二区)
[6] Jingbo Qin(#), Boning Niu(#), Xiaohui Chen(#), Cheng Hu, Sheng Lu, Hongsheng Li, Weihao Liu, Jiayi Li, Zihao Teng, Yinghuang Yang, Hongyu Hu, Yang Xu, Shuaidong Huo, Zhen Wu, Yingkun Qiu(*), Hu Zhou(*), and Meijuan Fang(*). Discovery of 5‑(Pyrimidin-2-ylamino)‑1H‑indole-2-carboxamide Derivatives as Nur77 Modulators with Selective and Potent Activity Against Triple-Negative Breast Cancer. J Med Chem, 2023 NOV 20; 66: 15847−15866. (JCR一区，药化TOP期刊)
[7] Zhijian Kuang(#), Kaiqiang Guo(#), Yin Cao(#), Mengxue Jiang(#), Chaojie Wang, Qiaoqiong Wu, Guosheng Hu, Mingtao Ao, Mingfeng Huang, Jingbo Qin, Taige Zhao, Sheng Lu, Cuiling Sun, Mingyu Li, Tong Wu(*), Wen Liu(*), Meijuan Fang(*). The novel CDK9 inhibitor, XPW1, alone and in combination with BRD4 inhibitor JQ1, for the treatment of clear cell renal cell carcinoma. Brit J Cancer, 2023 DEC 7; 129(12):1915 – 1929. (JCR一区，Nature Index, TOP期刊)
[8] Guiping Gao(#), Jiayi Li(#), Yin Cao, Xudan Li, Yuqing Qian, Xiumei Wang, Mengyu Li, Yingkun Qiu, Tong Wu(*), Liqiang Wang(*), Meijuan Fang(*). Design, synthesis, and biological evaluation of novel 4,4′-bipyridine derivatives acting as CDK9-Cyclin T1 protein-protein interaction inhibitors against triple-negative breast cancer. Eur J Med Chem, 2023 DEC 5; 261: 115858. (JCR一区，药化TOP期刊)
[9] Hua Fang, Mengyu Li, Xiumei Wang, Weizhu Chen, Fengming He, Yiping Zhang, Kaiqiang Guo, Wenhui Jin, Baicun Li(*), Meijuan Fang(*). Discovery of new DHA ethanolamine derivatives as potential anti-inflammatory agents targeting Nur77. Bioorg Chem, 2023 DEC; 141: 106887. (JCR一区)
[10] Hongyu Hu(#), Gang Lin(#), Fengming He, Jie Liu, Rong Jia, Kun Li, Wenbin Hong, Meijuan Fang(*), Jin-Zhang Zeng(*). Design, synthesis, and biological evaluation of carbonyl-hydrazine-1-carboxamide derivatives as anti-hepatic fibrosis agents targeting Nur77. Bioorg Chem, 2023 NOV; 140: 106795. (JCR一区)
[11] Yuqing Qian(#), Siyu Zhou(#), Jiayi Li(#), Mingyuan Ma(#), Huanwen Chen, Yin Cao, Yuxiang Zhang, Chaoyu Sun, Kang Li, Yizhao Liu, Shutong Dai, Mingtao Ao, Meijuan Fang(*), Zhen Wu(*), Mingdong Li(*). Discovery of 4-((3,4-dichlorophenyl)amino)-2-methylquinolin-6-ol derivatives as EGFR and HDAC dual inhibitors. Eur J Pharmacol, 2023 DEC 5; 960: 176114. (JCR一区)
[12] Fengming He(#), Jun Chen(#), Taige Zhao(#), Qiaoqiong Wu, Na Yin, Xiumei Wang, Yijing Zhong, Xiaodan Guo, YingKun Qiu, Baicun Li(*), Meijuan Fang(*), Zhen Wu(*). Design, synthesis, and evaluation of novel benzoylhydrazone derivatives as Nur77 modulators with potent antitumor activity against hepatocellular carcinoma, J Enzym Inhib Med Ch, 2023 DEC 31; 38(1): 2227777. (JCR一区)
[13] Chaojie Wang(#), Fengming He(#), Ke Sun(#), Kaiqiang Guo, Sheng Lu, Tong Wu(*), Xiang Gao(*), Meijuan Fang(*). Identification and characterization of 7-azaindole derivatives as inhibitors of the SARS-CoV-2 spike-hACE2 protein interaction. Int J Biol Macromol, 2023 JUL 31; 244: 125182. (JCR一区)
[14] Chenli Chang, Fengming He, Mingtao Ao, Jun Chen, Tao Yu, Weiyu Li, Baicun Li(*), Meijuan Fang(*), Ting Yang(*). Inhibition of Nur77 expression and translocation by compound B6 reduces ER stress and alleviates cigarette smoke-induced inflammation and injury in bronchial epithelial cells. Front Pharmacol. 2023 JUN 19; 14: 1200110. (JCR一区)
[15] Jun Chen(#), Taige Zhao(#), Fengming He, Yijing Zhong, Susu Wang, Ziqing Tang, Yingkun Qiu, Zhen Wu(*), Meijuan Fang(*). Discovery of bipyridine amide derivatives targeting pRXRα-PLK1 interaction for anticancer therapy. Eur J Med Chem, 2023 JUN 5; 254: 115341. (JCR一区，药化TOP期刊)
[16] Hua Fang(#), Yin Cao(#), JianYu Zhang, Xiumei Wang, Mengyu Li, Zhuan Hong, Zhen Wu, Meijuan Fang(*). Lipidome Remodeling Activities of DPA-EA in Palmitic Acid-Stimulated HepG2 Cells and The in vivo Anti-obesity Effect of the DPA-EA and DHA-EA Mixture Prepared from Algae Oil. Front Pharmacol, 2023 MAR 29; 14: 1146276. (JCR一区)
[17] Fengming He(#), Xiumei Wang(#), Qiaoqiong Wu, Shunzhi Liu, Yin Cao, Xiaodan Guo, Sihang Yin, Na Yin, Baicun Li(*), Meijuan Fang(*). Identification of potential ATP-competitive cyclin-dependent kinase 1 inhibitors: De novo drug generation, molecular docking, and molecular dynamics simulation. Comput Biol Med, 2023 MAR; 155: 106645. (JCR一区)
[18] Mingtao Ao(#), Jun Wu(#), Yin Cao, Yaohui He, Yuxiang Zhang, Xiang Gao, Yuhua Xue(*), Meijuan Fang(*), Zhen Wu(*), The synthesis of PROTAC molecule and new target KAT6A identification of CDK9 inhibitor iCDK9. Chinese Chem Lett, 2023 APR; 34: 107741. (JCR一区)
[19] Haofan Zhang(#), Fengming He(#), Guiping Gao, Sheng Lu, Qiaochu Wei, Hongyu Hu, Zhen Wu, Meijuan Fang(*), Xiumin Wang(*). Approved Small-Molecule ATP-Competitive Kinases Drugs Containing Indole/Azaindole/Oxindole Scaffolds: R&D and Binding Patterns Profiling. Molecules, 2023 FEB; 28(3): 943. (JCR二区)
[20] Jingbo Qin(#), Xiaohui Chen(#), Weihao Liu(#), Jun Chen, Weirong Liu, Yongzhen Xia , Zhehui Li, Mingyu Li, Shaojuan Wang, Quan Yuan, Yingkun Qiu(*), Zhen Wu(*), Meijuan Fang(*). Discovery of 5-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)-1H-indole-2-carboxamide derivatives as novel anti-cancer agents targeting Nur77. Eur J Med Chem, 2022 DEC 15; 244: 114849. (JCR一区，药化TOP期刊)
[21] Yuqing Qian(#), Mingtao Ao(#), Boqun Li(#), Zhijian Kuang, Xiumei Wang, Yin Cao, Jiayi Li, Yingkun Qiu, Kaiqiang Guo(*), Meijuan Fang(*), Zhen Wu(*). Design and synthesis of N-(1-(6-(substituted phenyl)-pyridazin-3-yl)-piperidine-3-yl)-amine derivatives as JMJD6 inhibitors. Bioorg Chem, 2022 DEC; 129: 106119. (JCR一区)
[22] Baicun Li(#), Jiangang Huang(#), Jie Liu(#), Fengming He, Fangfang Wen, Changming Yang, Wang Wang, Tong Wu, Taige Zhao, Jie Yao, Shunzhi Liu, Yingkun Qiu, Meijuan Fang(*), Jinzhang Zeng(*), Zhen Wu(*). Discovery of a Nur77-mediated cytoplasmic vacuolation and paraptosis inducer (4-PQBH) for the treatment of hepatocellular carcinoma. Bioorg Chem, 2022 APR; 121: 105651. (JCR一区)
[23] Mingtao Ao(#), Jianyu Zhang(#), Yuqing Qian(#), Boqun Li, Xiumei Wang, Jun Chen, Yuxiang Zhang, Yin Cao, Yingkun Qiu, Yang Xu(*), Zhen Wu(*), Meijuan Fang(*). Design and synthesis of adamantyl-substituted flavonoid derivatives as anti-inflammatory Nur77 modulators: Compound B7 targets Nur77 and improves LPS-induced inflammation in vitro and in vivo. Bioorg Chem, 2022 MAR; 120: 105645. (JCR一区)
[24] Jun Wu(#), Hongyu Hu(#), Mingtao Ao(#), Zhenzhen Cui, Xiaoping Zhou, Jingbo Qin, Yafei Guo, Jingwei Chen(*), Yuhua Xue(*), Meijuan Fang(*). Design, synthesis, and biological evaluation of 5-((4-(pyridin-3-yl)pyrimidin-2-yl) amino)-1H-Indole-2-Carbohydrazide derivatives: the methuosis inducer 12A as a novel and selective anticancer agent. J Enzym Inhib Med Ch, 2021 JAN 1; 36(1): 1436–1453. (JCR一区)
[25] Mingtao Ao(#), Xianwen Hu(#), Yuqing Qian(#), Boqun Li, Jianyu Zhang, Yin Cao, Yuxiang Zhang, Kaiqiang Guo, Yingkun Qiu, Fuquan Jiang(*), Zhen Wu(*), Meijuan Fang(*). Discovery of new chalone adamantyl arotinoids having RXRα-modulating and anticancer activities. Bioorg Chem, 2021 MAY; 113: 104961. (JCR一区)
[26] Baicun Li(#), Jie Yao(#), Fengming He(#), Jie Liu, Zongxin Lin, Shunzhi Liu, Wang Wang, Tong Wu, Jiangang Huang, Kun Chen, Meijuan Fang(*), Jingwei Chen(*), Jin-Zhang Zeng(*). Synthesis, SAR study, and bioactivity evaluation of a series of Quinoline-Indole-Schiff base derivatives: Compound 10E as a new Nur77 exporter and autophagic death inducer. Bioorg Chem, 2021 AUG; 113: 105008. (JCR一区)
[27] Jingbo Qin(#), Jie Liu(#), Chunxiao Wu, Jianwen Xu, Bowen Tang, Kaiqiang Guo, Xiaohui Chen, Weihao Liu, Tong Wu, Hu Zhou(*), Meijuan Fang(*), Zhen Wu(*). Synthesis and biological evaluation of (3/4-(pyrimidin-2-ylamino)benzoyl)-based hydrazine-1-carboxamide /carbothioamide derivatives as novel RXRα antagonists. J Enzym Inhib Med Ch, 2020 JAN 1; 35(1): 880–896. (JCR一区)
[28] Hua Fang, Jianyu Zhang, Mingtao Ao, Fengming He, Weizhu Chen, Yuqing Qian, Yuxiang Zhang, Yang Xu(*), Meijuan Fang(*). Synthesis and discovery of ω-3 polyunsaturated fatty acid- alkanolamine (PUFA-AA) derivatives as anti-inflammatory agents targeting Nur77. Bioorg Chem, 2020 DEC; 105: 104456. (JCR一区)
[29] Hongyu Hu(#), Jun Wu(#), Mingtao Ao(#), Xiaoping Zhou, Boqun Li, Zhenzhen Cui, Tong Wu, Lijuan Wang, Yuhua Xua(*), Zhen Wu(*), Meijuan Fang(*). Design, synthesis and biological evaluation of methylenehydrazine-1-carboxamide derivatives with (5-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)-1H-indole scaffold: Novel potential CDK9 inhibitors. Bioorg Chem, 2020 SEP; 102: 104064. (JCR一区)
[30] Baicun Li(#), Jie Yao(#), Kaiqiang Guo(#), Fengming He, Kun Chen, Zongxin Lin, Shunzhi Liu, Jiangang Huang, Qiaoqiong Wu, Meijuan Fang(*), Jinzhang Zeng(*), Zhen Wu(*). Design, synthesis, and biological evaluation of 5-((8-methoxy-2-methylquinolin-4-yl)amino)-1H-indole-2-carbohydrazide derivatives as novel Nur77 modulators. Eur J Med Chem, 2020 OCT 15; 204: 112608. (JCR一区，药化TOP期刊)
[31] Baicun Li(#), Feifeng Zhu(#), Fengming He(#), Qingqing Huang, Xiaoguang Liu, Tong Wu, Taige Zhao, Yingkun Qiu, Zhen Wu, Yuhua Xue(*), Meijuan Fang(*). Synthesis and biological evaluations of N’-substituted methylene-4-(quinoline-4-amino) benzoylhydrazides as potential anti-hepatoma agents. Bioorg Chem, 2020 MAR; 96: 103592. (JCR一区)
[32] Fengming He(#), Wang Cong(#), Cao Yin, Chenfan Li, Shengxian Zhao, Zhen Wu, Hongyu Hu(*), Meijuan Fang(*). Design, synthesis, and biological evaluation of (E)-N‘-substitute-4-((4-pyridylpyrimidin-2-yl)amino) benzohydrazide derivatives as novel potential CDK9 inhibitors. Arab J Chem, 2022 SEP; 15(9): 104039. (JCR二区)
[33] Hua Fang, Honghui Guo, Hui Chen, Zhuan Hong(*), Meijuan Fang(*). Novel derivatives of salicylanilide: Synthesis, characterization, PPO inhibitory activity and cytotoxicity. J Mol Struct, 2021 JAN 5; 1223: 128995. (JCR二区)
[34] Jun Wu, Yafei Guo, Jun Chen, Sangsang Hu, Ke Sun, Hongyu Hu(*), Meijuan Fang(*), Yuhua Xue(*). Synthesis and Antiproliferative Activity of New Thiosemicarboxamide Derivatives. Chem Biodivers, 2021 DEC; 18(12): e202100671. (JCR三区)
[35] Kaiqiang Guo(#), Yin Cao(#), Zan Li, Xiaoxiao Zhou, Rong Ding, Kejing Chen, Yan Liu, Yingkun Qiu, Zhen Wu(*), Meijuan Fang(*). Glycine metabolomic changes induced by anticancer agents in A549 Cells. Amino Acids, 2020 MAY; 52(5): 793~809. (JCR三区)
[36] Hua Fang, Mengyu Li, Hui Chen, Jun Chen, Zhuan Hong, Weizhu Chen(*), Meijuan Fang(*). Study on Salicylanilide Analogue for Antioxidant Activity and Melanosis Prevention in Chinese White Shrimp (Fenneropenaeus chinensis), J Aquat Food Prod T, 2022 MAY 28; 31(5): 410-417. (JCR四区)
代表性专利
1.吴振，方美娟，秦静波，周虎，陈俊，刘伟豪，牛播宁，陈晓惠，N-取代-5-((4-取代嘧啶-2-基)氨基)-1H-吲哚-2-甲酰胺衍生物，专利号：ZL 2022 1 0149370.6，专利授权日：2024年7月19日。
2.吴振，刘文，方美娟，郭凯强，匡志坚，王超杰，陈静威，陈俊，秦静波，一种CDK9抑制化合物及其应用，专利号：ZL 2021 1 0628859.7，专利授权日：2024年4月5日。
3.吴振，方美娟，陈俊，赵泰格，何凤明，钟艺晶，联吡啶酰胺类衍生物及其制备和应用，专利号：ZL 2023 1 0132225.1，专利授权日：2024年8月20日。
4.吴振，方美娟，刘文，钱宇卿，敖名涛，曹银，王秀美，李博群，张宇翔，N-(1-(6-(取代苯基)哒嗪-3-基)哌啶-3-基)胺/酰胺衍生物及制备方法，专利号：ZL 2022 1 1044195.0，专利授权日：2023年6月13日。
5.吴振，郭凯强，方美娟，王超杰，吴巧琼，钱宇卿，刘伟豪，何凤明，高原；3-取代基-5-（取代芳基）-7-氮杂吲哚衍生物及其应用，专利号：202110554512.2，专利授权日：2022年4月12日。
6.方美娟，吴振，郭凯强，王超杰，曹银，秦静波，陈静威，赵泰格；(1H-咪唑并[4,5-b]吡啶-6-基)吡啶衍生物及其应用，专利号：202010240017.X，专利授权日：2021年10月15日。
7.吴振，周虎，方美娟，秦静波，牛播宁，王超杰，陈晓惠，唐博文，曹银，吕奔；嘧啶吲哚类Nur77受体调控剂及其制备方法和应用，专利号：201910105476.4；专利授权日：2021年04月09日。
8.刘文，吴振，方美娟，李柏村，黄建刚，杨沫，唐博文，李博群，王浩杰，主父学良；一类4-（（2-取代喹啉-4-基）氨基）苯甲酰肼类衍生物及其制备方法与应用，专利号：201810253238.3；专利授权日：2020年11月10日。
9.吴振，方美娟，秦静波，陈晓惠，唐博文，郭凯强；N-取代-5-（（4-取代嘧啶-2-基）氨基）吲哚类衍生物及其制备方法和用途，专利号：201710950061.8；专利授权日：2020年02月14日。
10.吴振，方美娟，秦静波，胡鸿雨，林春蓉，钱宇卿；1-(2-(碳酰肼取代基团)-1H-吲哚-5-基)-3-取代脲衍生物及制备方法，专利号：2015107498281；专利授权日：2019年02月05日。
联系方式：fangmj@xmu.edu.cn
地址：福建省厦门市翔安区翔安南路厦门大学药学院
邮编：361102
